{
    "nct_id": "NCT01764243",
    "title": "A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.",
    "status": "COMPLETED",
    "last_update_time": "2015-09-24",
    "description_brief": "The objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "MT-4666 (encenicline, EVP\u20116124)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests MT-4666 (listed in the protocol as MT\u20114666) with a cognitive primary efficacy measure (ADAS\u2011cog\u201113) over 24 weeks in mild\u2013moderate AD, which indicates the intended effect is improving cognition rather than targeting amyloid or tau pathology. \ue200cite\ue202turn0search0\ue201",
        "Act: MT\u20114666 is the development code for encenicline (also known as EVP\u20116124), a selective \u03b17 nicotinic acetylcholine receptor (nAChR) partial agonist \u2014 a small\u2011molecule, pro\u2011cognitive mechanism (cholinergic/nicotinic modulation) rather than a biologic targeting AD pathology. Based on that mechanism and the ADAS\u2011cog endpoint, this fits the 'cognitive enhancer' category. \ue200cite\ue202turn1search1\ue202turn1search3\ue201",
        "Reflect: Classification check \u2014 encenicline/MT\u20114666 is a small molecule acting on \u03b17 nAChRs (procognitive), not a monoclonal antibody or vaccine and not primarily intended for neuropsychiatric symptom relief; therefore 'cognitive enhancer' is the appropriate category. Clinical program pages list MT\u20114666/encenicline for cognitive impairment in AD, supporting this interpretation. \ue200cite\ue202turn1search0\ue202turn1search6\ue201",
        "Web search results (key sources used):",
        "- Clinical trial record for 'Safety and Efficacy of MT\u20114666' (Phase 2) showing ADAS\u2011cog\u201113 primary assessment and 24\u2011week daily dosing in mild\u2013moderate AD. \ue200cite\ue202turn0search0\ue201",
        "- Pharmacodynamics/pharmacokinetics publications describing encenicline (EVP\u20116124) as a selective \u03b17 nicotinic acetylcholine receptor partial agonist developed for cognitive impairment. \ue200cite\ue202turn1search3\ue201",
        "- Clinical reports and product listings mapping MT\u20114666 to encenicline/EVP\u20116124 and describing its \u03b17 nAChR partial agonist (procognitive) activity. \ue200cite\ue202turn1search1\ue202turn1search0\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The protocol tests MT-4666 (encenicline) with a cognitive primary efficacy measure (ADAS-cog-13) in mild\u2013moderate AD, indicating the intended effect is pro-cognitive modulation of neurotransmission rather than targeting amyloid or tau pathology. \ue200cite\ue202turn1search0\ue201",
        "Act: MT-4666 is the development code for encenicline (EVP\u20116124/MT\u20114666), a selective partial agonist of the \u03b17 nicotinic acetylcholine receptor (a neuronal neurotransmitter receptor). This is a small\u2011molecule cholinergic/nicotinic receptor modulator (procognitive mechanism), which maps to CADRO category D: Neurotransmitter Receptors. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Classification check \u2014 encenicline\u2019s documented pharmacology (\u03b17 nAChR partial agonism) and its use to improve cognition (ADAS\u2011cog endpoint) align with CADRO D (Neurotransmitter Receptors). The trial is not primarily anti-amyloid, anti\u2011tau, anti\u2011inflammatory, nor a diagnostic procedure, and it targets a single receptor class rather than multiple distinct pathological pathways, so 'D) Neurotransmitter Receptors' is the appropriate assignment. \ue200cite\ue202turn0search2\ue202turn1search8\ue201",
        "Web search results (key sources used):",
        "- PubMed pharmacology of EVP\u20116124 describing selective \u03b17 nAChR partial agonism. \ue200cite\ue202turn0search0\ue201",
        "- Preclinical pharmacology showing neurotransmitter release effects and procognitive activity for EVP\u20116124. \ue200cite\ue202turn0search1\ue201",
        "- Alzforum therapeutic profile linking encenicline (EVP\u20116124 / MT\u20114666) to procognitive \u03b17 nAChR activity. \ue200cite\ue202turn0search2\ue201",
        "- Clinical trial registry for 'Safety and Efficacy of MT\u20114666' (Phase 2) listing ADAS\u2011cog\u201113 as the primary efficacy measure and 24\u2011week dosing in mild\u2013moderate AD. \ue200cite\ue202turn1search0\ue202turn1search1\ue201"
    ]
}